Literature DB >> 12237507

The validity of the GaitRite and the Functional Ambulation Performance scoring system in the analysis of Parkinson gait.

Arthur J Nelson1, Dalia Zwick, Susan Brody, Christine Doran, Lori Pulver, Gitty Rooz, Marla Sadownick, Roger Nelson, Jeffrey Rothman.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this study was (1) to determine the validity of the GaitRite System in detecting footfall patterns and selected gait characteristics of person with early stage Parkinson's disease (PD) and (2) to investigate whether the Functional Ambulation Performance (FAP) scoring system is a valid tool to distinguish between selected gait characteristics of patients with early stage Parkinson's disease and similar age of non-impaired individuals. The FAP score is a quantitative means of assessing gait based on specific spatial and temporal gait parameters. PARTICIPANTS: 11 volunteers with idiopathic Parkinson's disease, (mean age = 74.3), and 11 age matched volunteers, (mean age = 70.3), with no history of neurological disorder participated in the study. The non-impaired control group were not matched in age and sex but of similar age and males and females were represented in the control group.
METHODS: Temporal and spatial parameters of gait were analyzed for both preferred- speed and fast-speed walking using the computerized GaitRite system. The system integrates specific components of locomotion to provide a single, numerical representation of gait, the Functional Ambulation Performance Score (FAP) score.
RESULTS: The most powerful and discriminating variable between Parkinson's and non-impaired groups for both walking speeds was the mean normalized velocity (MNV). Which is velocity divided by leg length. The MNV was 0.83 for PD at preferred walking speed and 1.14 at fast speed, the non-impaired group preferred-speed group walking was 1.33, while fast-speed walking MNV was 1.70. Note the fast walking of PD was slower than the preferred velocity of the non-impaired group. For preferred-speed walking, all gait variables analyzed in the study were different between the two groups beyond the p < 0.05 level of confidence with the single exception of right stance percentage. For fast-speed walking, three of the entered variables did not discriminate between the two groups: the fast walking FAP score, left fast-walking cadence, and right fast-walking single support percentage. CONCLUSION AND DISCUSSION: Our results indicate that persons with Parkinson's disease (PD) attain a significantly lower FAP score when ambulating at their preferred rate and demonstrate shorter step length and a longer step time than the age matched non-impaired group during both preferred and fast velocities of walking. Stance duration and double support duration were increased for the Parkinson's population, whereas single support duration, mean cadence, and heel-to-heel base of support were markedly reduced for both walking speeds. The FAP score was significantly different from the non-impaired control group for preferred-speed walking. These results indicate that the GaitRite system can be useful in detecting footfall patterns and selected time and distance measurements of persons with early stage Parkinson's disease and the FAP score discriminates between the PD population and the non-impaired controls when walking at preferred rate but not at fast walking.

Entities:  

Mesh:

Year:  2002        PMID: 12237507

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  33 in total

1.  Effects of levodopa on forward and backward gait patterns in persons with Parkinson's disease.

Authors:  M S Bryant; D H Rintala; J G Hou; E C Lai; E J Protas
Journal:  NeuroRehabilitation       Date:  2011       Impact factor: 2.138

2.  Assessment of gait parameters and fatigue in MS patients during inpatient rehabilitation: a pilot trial.

Authors:  Rosaria Sacco; Rita Bussman; Peter Oesch; Jürg Kesselring; Serafin Beer
Journal:  J Neurol       Date:  2010-11-15       Impact factor: 4.849

Review 3.  Assessing the interplay between cognition and gait in the clinical setting.

Authors:  A H Snijders; C C Verstappen; M Munneke; B R Bloem
Journal:  J Neural Transm (Vienna)       Date:  2007-07-06       Impact factor: 3.575

4.  Short duration, intensive tango dancing for Parkinson disease: an uncontrolled pilot study.

Authors:  Madeleine E Hackney; Gammon M Earhart
Journal:  Complement Ther Med       Date:  2009-01-07       Impact factor: 2.446

5.  Classification of Normal and Pathological Gait in Young Children Based on Foot Pressure Data.

Authors:  Guodong Guo; Keegan Guffey; Wenbin Chen; Paola Pergami
Journal:  Neuroinformatics       Date:  2017-01

6.  Backward walking in Parkinson's disease.

Authors:  Madeleine E Hackney; Gammon M Earhart
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

Review 7.  The First Frontier: Digital Biomarkers for Neurodegenerative Disorders.

Authors:  E Ray Dorsey; Spyros Papapetropoulos; Mulin Xiong; Karl Kieburtz
Journal:  Digit Biomark       Date:  2017-07-04

8.  Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Chieh-Sen Chuang; Hong-Lin Su; Fu-Chou Cheng; Shan-hui Hsu; Chi-Fen Chuang; Chin-San Liu
Journal:  J Biomed Sci       Date:  2010-02-13       Impact factor: 8.410

Review 9.  Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease.

Authors:  Christiana Ossig; Angelo Antonini; Carsten Buhmann; Joseph Classen; Ilona Csoti; Björn Falkenburger; Michael Schwarz; Jürgen Winkler; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2015-08-08       Impact factor: 3.575

10.  Differentiating shunt-responsive normal pressure hydrocephalus from Alzheimer disease and normal aging: pilot study using automated MRI brain tissue segmentation.

Authors:  Yafell Serulle; Henry Rusinek; Ivan I Kirov; Hannah Milch; Els Fieremans; Alexander B Baxter; John McMenamy; Rajan Jain; Jeffrey Wisoff; James Golomb; Oded Gonen; Ajax E George
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.